Vaginal Probiotics During Pregnancy After Premature (24-32 Weeks of Gestation) Preterm Rupture of Membranes
Ориентир для пациента и семьи
Простыми словами
Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.
- Что изучают
- В протоколе указаны: Probiotic, Placebo.
- Кому может быть актуально
- Состояния в реестре: Pregnancy, Prematurity, PPROM. Базовые параметры: от 18 лет · Женщины.
- Что важно проверить
- Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
- Где проводится
- Канада
- Следующий шаг
- Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →
Не всё понятно в терминах? Прочитайте наш гид для пациентов →
Официальное название
Multicentric Clinical Pilot Trial Testing the Association Between Antibiotics and Vaginal Probiotics for Patients With Prematured Rupture of Membranes Between 24 and 32 Weeks of Amenorrhea ( PROB-PROM Study)
Обзор
The goal of this clinical trial is to evaluate the feasibility of the randomized controlled trial (RCT). Secondary objectives include comparing the microbiota of preterm babies born after premature rupture of membranes across study groups. To achieve this, participants will be asked to: * Use the vaginal study product from the time of membrane rupture until delivery * Keep a diary documenting their symptoms and treatment adherence * Provide vaginal secretion samples and stool samples from their baby
Подробное описание
Premature rupture of fetal membranes before labor (PPROM) accounts for 30% of preterm births. Since PPROM is strongly associated with ascending vaginal infection, antibiotics are recommended during the latent period (LP) (the interval between rupture and birth). While they prolong the LP and improve neonatal health, they also exacerbate pre-existing vaginal dysbiosis. The addition of vaginal probiotics (VP) helps stabilize the vaginal microbiota (VM) and increase Lactobacillus levels. By enhancing the presence of beneficial bacteria in the vagina, probiotics help restore the balance between beneficial and pathogenic microbes, potentially reducing uterine infection and improving the fetal intestinal microbiota.
Pathophysiological Hypotheses for Improving Neonatal Health
The use of VP may influence neonatal outcomes through three potential mechanisms:
i) Reduction of vaginal dysbiosis: Prolongs pregnancy and mitigates complications related to fetal immaturity (e.g., decreases risk of intraventricular hemorrhage).
ii) Reduction of intrauterine infection/inflammation: Lowers neonatal complications associated with inflammation (e.g., reduces incidence of cystic periventricular leukomalacia).
iii) Improvement of neonatal intestinal microbiota (NIM) through probiotic ingestion: Decreases complications linked to neonatal dysbiosis (e.g., reduces risk of necrotizing enterocolitis \[NEC\]).
Primary Objectives
* To assess the validity of:
i) A recruitment rate \> 35% ii) A treatment adherence rate \> 80% iii) A sample attrition rate \< 5% * To identify barriers and facilitators in different settings for the implementation of the randomized controlled trial (RCT).
Secondary Objectives
* To compare the presence of probiotics in the vaginal microbiota and neonatal stool (meconium and at 7 days of life). * To measure the effect of probiotics on the evolution of maternal vaginal microbiota and neonatal intestinal microbiota.
Population Pregnant women aged 18 years or older giving birth at one of the eight centers participating in the study in Quebec and Ontario, Canada. Participants will be randomly assigned, in a blinded manner, to either the probiotic or placebo group.
Вмешательства
- Другое Probiotic
Participant will take 1 intravaginal capsule once a day at bedtime between inclusion in the study until delivery - Другое Placebo
Participant will take 1 intravaginal capsule once a day at bedtime between inclusion in the study until delivery
Первичные конечные точки
- Recruitment rate [Срок оценки: 7 months]
- Feasability dashboard [Срок оценки: 7 months]
- Treatment adherence [Срок оценки: 7 months]
Вторичные конечные точки (1)
- Probiotics primers [Срок оценки: From enrollement to infant 7th day of life]
Критерии участия
Критерии включения
- women ≥ 18 years of age;
- mono-fetal pregnancy;
- treated for PPROM between 24 and 32 weeks of gestation with latency period between 12 hours and < 7 days in one of the study centers with expectant management;
- speaking and able to read French or English.
Критерии исключения
- Presence of active labor;
- Situation contraindicating expectant management (e.g., infection);
- Significant malformation, chromosomal anomaly, or fetal death;
- Signs of fetal distress;
- Allergy or intolerance to any of the following substances: vitamin C (ascorbic acid), magnesium stearate, maltodextrin, gelatin, yeast, sucrose, trehalose;
- Allergy to soy or lactose;
- Weakened immune system (e.g., AIDS, prolonged corticosteroid treatment, etc.);
- Vaginal probiotics intake 15 days before study inclusion;
- Oral probiotic intake 30 days before study inclusion.
Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.
Здоровые добровольцы: Нет
Дизайн исследования
- Распределение
- Рандомизированное
- Модель
- Параллельные группы
- Маскирование
- Четверное слепое
- Основная цель
- Лечение
Центры проведения
Канада · 1 центр
- Centre de recherche du CHUM — Montreal
Идентификаторы
NCT: NCT06965049 · MP-02-2025-12882